These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

858 related items for PubMed ID: 15456950

  • 21. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
    Kakolyris S, Papadakis E, Tsiafaki X, Kalofonos C, Rapti A, Toubis M, Bania E, Kouroussis C, Chainis K, Androulakis N, Agelaki S, Sarra E, Vardakis N, Georgoulias V, Greek Cooperative Group for Lung Cancer.
    Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
    [Abstract] [Full Text] [Related]

  • 22. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
    Kosmas C, Tsavaris N, Vadiaka M, Stavroyianni N, Koutras A, Malamos N, Onyenadum A, Rokana S, Polyzos A, Kalofonos HP.
    Cancer; 2001 Dec 01; 92(11):2902-10. PubMed ID: 11753965
    [Abstract] [Full Text] [Related]

  • 23. [Phase III clinical trials concerning non-small-cell lung carcinoma (NSCLC) presented at the ASCO 2001].
    Morere JF.
    Rev Pneumol Clin; 2001 Nov 01; 57(5 Pt 2):S37-41. PubMed ID: 11924242
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [Gemcitabine].
    Takeda K.
    Nihon Rinsho; 2002 May 01; 60 Suppl 5():359-65. PubMed ID: 12101689
    [No Abstract] [Full Text] [Related]

  • 28. Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.
    Rigas JR.
    Semin Oncol; 2001 Jun 01; 28(3 Suppl 9):15-20. PubMed ID: 11441410
    [Abstract] [Full Text] [Related]

  • 29. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
    Kosmas C, Tsavaris N, Syrigos K, Koutras A, Tsakonas G, Makatsoris T, Mylonakis N, Karabelis A, Stathopoulos GP, Kalofonos HP.
    Cancer Chemother Pharmacol; 2007 Jan 01; 59(1):51-9. PubMed ID: 16622691
    [Abstract] [Full Text] [Related]

  • 30. Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study.
    Douillard JY, Gervais R, Dabouis G, Le Groumellec A, D'Arlhac M, Spaeth D, Coudert B, Caillaud D, Monnier A, Clary C, Maury B, Mornet M, Rivière A, Clouet P, Couteau C.
    Ann Oncol; 2005 Jan 01; 16(1):81-9. PubMed ID: 15598943
    [Abstract] [Full Text] [Related]

  • 31. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
    Evans WK, Kocha W, Gagliardi A, Eady A, Newman TE.
    Cancer Prev Control; 1999 Feb 01; 3(1):84-94. PubMed ID: 10474757
    [Abstract] [Full Text] [Related]

  • 32. Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104).
    Takeda K, Negoro S, Tamura T, Nishiwaki Y, Kudoh S, Yokota S, Matsui K, Semba H, Nakagawa K, Takada Y, Ando M, Shibata T, Saijo N.
    Ann Oncol; 2009 May 01; 20(5):835-41. PubMed ID: 19164456
    [Abstract] [Full Text] [Related]

  • 33. Vinorelbine, ifosfamide, and cisplatin combination as salvage chemotherapy in advanced non-small cell lung cancer.
    Song SY, Kim WS, Kim K, Jung CW, Im YH, Kim HJ, Kang WK, Lee HG, Kwon OJ, Rhee CH, Park CH, Park K.
    Jpn J Clin Oncol; 2003 Oct 01; 33(10):509-13. PubMed ID: 14623918
    [Abstract] [Full Text] [Related]

  • 34. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Burris HA, Billings FT, Bradof JE, Baker M, Greco FA.
    Cancer; 2001 Nov 01; 92(9):2391-8. PubMed ID: 11745295
    [Abstract] [Full Text] [Related]

  • 35. Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer.
    Lee DH, Han JY, Cho KH, Pyo HR, Kim HY, Yoon SJ, Lee JS.
    Int J Radiat Oncol Biol Phys; 2005 Nov 15; 63(4):1037-44. PubMed ID: 16024178
    [Abstract] [Full Text] [Related]

  • 36. A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status.
    Cobo M, Gutiérrez V, Alcaide J, Alés I, Villar E, Gil S, Durán G, Martínez J, Carabantes F, Bretón JJ, Benavides M.
    Lung Cancer; 2007 May 15; 56(2):255-62. PubMed ID: 17276537
    [Abstract] [Full Text] [Related]

  • 37. Development of docetaxel in advanced non-small-cell lung cancer.
    Belani CP, Eckardt J.
    Lung Cancer; 2004 Dec 15; 46 Suppl 2():S3-11. PubMed ID: 15698529
    [Abstract] [Full Text] [Related]

  • 38. A phase II study with vinorelbine, gemcitabine and cisplatin in the treatment of patients with stage IIIb-IV non-small cell lung cancer (NSCLC).
    Ginopoulos P, Mastronikolis NS, Giannios J, Karana A, Siabi V, Karvelas F, Rathossis S, Apostolopoulos N, Mastorakou A.
    Lung Cancer; 1999 Jan 15; 23(1):31-7. PubMed ID: 10100144
    [Abstract] [Full Text] [Related]

  • 39. Phase I/II study of gemcitabine and vinorelbine plus cisplatin in non-small cell lung cancer.
    Esteban E, Fra J, Sala M, Carrasco J, Corral N, Vieitez JM, Estrada E, Palacio I, Buesa JM, Lacave AJ.
    Invest New Drugs; 2002 Aug 15; 20(3):317-26. PubMed ID: 12201494
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.